Baoqi Li

Title: Innovations in Pharmaceutical Composition by Baoqi Li

Introduction

Baoqi Li is a notable inventor based in Tianjin, China. He has made significant contributions to the field of pharmaceutical compositions, particularly in the treatment of sepsis. His innovative work has led to the development of effective drug formulations that are both safe and efficacious.

Latest Patents

Baoqi Li holds a patent for a pharmaceutical composition aimed at treating sepsis. This patent includes a three-component formulation consisting of hydroxysafflower yellow A (HSYA), paeoniflorin, and albiflorin. Additionally, he has developed a seven-component pharmaceutical composition that incorporates HSYA, paeoniflorin, albiflorin, oxypaeoniflorin, senkyunolide I, salvianic acid A sodium (SAAS), and ferulic acid. Both formulations have been verified at the cellular and animal levels for their effectiveness in treating sepsis, while also demonstrating safety in drug toxicity experiments. This pharmaceutical composition serves as an active ingredient in the Xuebijing Injection, which is utilized for clinical treatment of sepsis.

Career Highlights

Baoqi Li is associated with Tianjin Chase Sun Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work has garnered attention for its potential impact on clinical practices and patient outcomes.

Collaborations

He collaborates with esteemed colleagues such as Yang Yu and Jianli Wang, contributing to a dynamic research environment that fosters innovation.

Conclusion

Baoqi Li's contributions to pharmaceutical compositions represent a significant advancement in the treatment of sepsis. His innovative formulations are paving the way for safer and more effective clinical treatments.